Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TroFuse-036 first-line maintenance therapy in metastatic cervical cancer
jRCT2031250604Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan, pembrolizumab and bevacizumab in Cervical Cancer (CC), cervical adenocarcinoma, cervical squamous cell carcinoma (CSCC) and 1 more (3 arms), sponsored by Merck & Co. Started Jan 2026; status: recruiting.
02
Drugs
03
Conditions
Cervical Cancer (CC)cervical adenocarcinomacervical squamous cell carcinoma (CSCC)Adenosquamous Cervical Cancer (ASC)
Beyond the preview
Go deeper on jRCT2031250604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250604.